Riskpilot← Back to searchSign inGet full accessPROTERAPI A/S
A/SDissolvedCVR 18735202Industriparken 25Wholesale of pharmaceutical and medical goods · NACE 4646Est. 19952 employees
Revenue 2021
DKK 6,6M
-5% vs 2020
EBITDA margin
-3.8%
-128% vs 2020
Equity ratio
9.1%
Financial strength
Net profit 2021
DKK -223K
-146% vs 2020
| Revenue | DKK 6,6M | -5% |
| EBITDA | DKK -248K | -128% |
| Net profit | DKK -223K | -146% |
| Total assets | DKK 13,3M | +23% |
| Equity | DKK 1,2M | -16% |
| Employees | 2 | — |
Legal name
PROTERAPI A/S
CVR number
18735202
Legal form
Aktieselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
3. august 1995
Share capital
DKK 500.000
Employees
2 (FTE)
VAT registered
No
Audit selected
No
Last report
2021-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør alene, af et bestyrelsesmedlem og en direktør i
forening eller af to bestyrelsesmedlemmer i forening.
Address
Industriparken 25
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.000 | 11.600 | 11.176 | 10.149 | 13.995 | 11.045 | 9.295 | 6.664 | 6.938 | 6.585 |
| Staff expenses | -5.174 | -6.252 | -6.061 | -6.232 | -9.078 | -8.103 | -7.412 | -6.609 | -6.038 | -6.832 |
| EBITDA | 3.826 | 5.348 | 5.115 | 3.917 | 4.917 | 2.942 | 1.882 | 55 | 899 | -248 |
| Depreciation & amort. | -460 | -469 | -553 | -513 | -621 | -550 | -433 | -170 | -98 | -25 |
| EBIT | 3.366 | 4.879 | 4.562 | 3.404 | 4.297 | 2.393 | 1.450 | -115 | 801 | -273 |
| Net financials | 14 | 10 | 3 | -21 | -189 | -87 | -118 | -118 | -170 | -12 |
| Profit before tax | 3.380 | 4.889 | 4.566 | 3.383 | 4.107 | 2.306 | 1.332 | -233 | 631 | -286 |
| Tax | 845 | 1.223 | 1.118 | 786 | 918 | 508 | 295 | -51 | 149 | -62 |
| Net profit | 2.535 | 3.666 | 3.448 | 2.597 | 3.189 | 1.799 | 1.037 | -182 | 482 | -223 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 9.687 | 10.073 | 10.517 | 9.818 | 14.057 | 18.050 | 12.223 | 9.463 | 10.838 | 13.293 |
| Equity | 3.909 | 3.575 | 4.023 | 3.320 | 3.009 | 2.299 | 1.537 | 946 | 1.428 | 1.205 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 54 | 110 | 112 |
| Short-term debt | 5.718 | 6.392 | 6.383 | 6.385 | 10.736 | 15.658 | 10.686 | 8.463 | 9.299 | 11.977 |
| Total debt | 5.718 | 6.392 | 6.383 | 6.385 | 10.736 | 15.658 | 10.686 | 8.517 | 9.410 | 12.088 |
EBITDA margin
-3.8%
This company
15.8%
Market median
-124% vs market
20122021
Equity ratio
9.1%
This company
38.2%
Market median
-76% vs market
20122021
Return on equity
-18.5%
This company
18.4%
Market median
-201% vs market
20122021
Net profit margin
-3.4%
This company
8.1%
Market median
-142% vs market
20122021
Asset turnover
0.50×
This company
1.12×
Market median
-55% vs market
20122021
Debt / equity
10.03×
This company
0.62×
Market median
-1518% vs market
20122021
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2015-07-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2014-07-01 – 2015-06-30
- Annual report 2014Filed via CVR / Virk · Period 2013-07-01 – 2014-06-30
- Annual report 2013Filed via CVR / Virk · Period 2012-07-01 – 2013-06-30
- Annual report 2012Filed via CVR / Virk · Period 2011-07-01 – 2012-06-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
MB Chief Executive Officer | Chief Executive Officer | 2019 | — | — |
DM Management | Management | 2012 | — | — |
EV Management | Management | 1996 | — | — |
MF Management | Management | 1995 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2015 | — | — | |
| Board of Directors | 1995 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2017 | — | — | |
| Board of Directors | 2015 | — | — | |
| Board of Directors | 2003 | — | — | |
| Board of Directors | 2015 | — | — | |
| Chairman | 2003 | — | — | |
| Chairman | 1995 | — | — | |
| Chairman | 2019 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
ANGINSAN HOLDING ApS | Company | 25.0% | 0.0% | 2015 |
JERSIE HOLDING ApS | Company | 20.0% | 100.0% | 2015 |
PROTERAPI HOLDING ApS | Company | 20.0% | 0.0% | 2015 |
Fitness & Healthcare Group A/S | Company | 100.0% | 100.0% | 2021 |
FROMIUM HOLDING ApS | Company | 25.0% | 0.0% | 2015 |
Healthcare Holding A/S | Company | 100.0% | 100.0% | 2015 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of PROTERAPI A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Michael Bøgh Larsen | Chief Executive Officer | 0 companies |
| Dorte Munch Ekstrand | Management | 0 companies |
| Erik Viggo From | Management | 0 companies |
| Morten Falck Larsen | Management | 0 companies |
| Gunnar Christian Kristensen | Board of Directors | 0 companies |
| Claes James Heerup | Board of Directors | 0 companies |
| Morten Damgaard | Board of Directors | 0 companies |
| Mikael Sternberg | Board of Directors | 0 companies |
| Torben Aagaard | Board of Directors | 0 companies |
| Kenneth Myrthue Sørensen | Board of Directors | 0 companies |
| Keld Norup Lauridsen | Board of Directors | 0 companies |
| Preben Edvard Kønig | Chairman | 0 companies |
| Keld Holm Sørensen | Chairman | 0 companies |
| Bjørn Barsø | Chairman | 0 companies |